Unmatched performance and precision with Philips MR 7700


Hitesh

In this webinar, you will hear from Frank Hoogenraad, the Senior Product Manager for 3T at Philips who will share details about the Philips MR 7700, the latest innovation in their 3T portfolio. With XP gradients and artificial intelligence, the system is built to address the most pressing needs in […]

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company


Hitesh

In addition to announcing preliminary unaudited fourth quarter and full year 2022 revenue, Deciphera Pharmaceuticals, Inc., a biopharmaceutical company dedicated to discovering, developing, and commercialising significant new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2023 and planned 2023 corporate milestones. Deciphera revealed […]

Mental Health In The Workplace


Hitesh

Employees and HR officials concur that treating workers’ mental health concerns is a major priority, according to recent workplace surveys and publications. However, it’s time to think about where this consensus will go and which workplace mental health issues will receive the most attention as we move ahead to 2023. […]

Polysciences Announces New Bioprocessing Brand, Kyfora Bio


Hitesh

Kyfora Bio will represent Polysciences, Inc.’s product offerings to the bioprocessing market as a maker of specialised chemicals for research, IVD, and medical device applications with a base in Pennsylvania. Kyfora Bio will concentrate on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for […]

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates


Hitesh

The COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates will now be tested in a Phase 2 trial, according to Novavax, Inc., a biotechnology company committed to creating and marketing next-generation vaccines for critical infectious diseases. The CIC and influenza vaccine candidates will be evaluated for safety and efficacy (immunogenicity) […]